Investigation in Russia and Azerbaijan showed the safety of the combination of the Vaccine Astrazeneca and Satellite Light, the Russian Funds of Direct Investments (RFI) says.
“RDII, Astrazeneca and R-Farm announced intermediate results of the II phase of clinical research on the safety assessment of the combined application of the Astrazeneca vaccine and the product” Satellite Light “. In the course of research with the participation of 100 volunteers in Russia and 100 volunteers in Azerbaijan The combination of drugs demonstrated the optimal profile of safety and tolerability, which correlates with the results of previously conducted clinical studies, “the Press Release of the RDII, which quotes TASS.
It is noted that the monitoring of volunteers continued within 57 days after the first vaccination and demonstrated high safety indicators of the combined use of drugs. During the observation, there was no serious undesirable phenomena related to vaccination.
RDII, Center for them. Gamaley, Astrazeneca and R-Farm, the first in the world launched a clinical studies program, within which the combined use of different adenoviral vaccines is estimated to prevent coronavirus infection, resembles agency. In December 2021, the World Health Organization (WHO) recommended such an approach, also known as heterologous prime-boob vaccination, for use in real clinical practice. According to WHO estimates, heterologous vaccination schemes with different drugs will ensure greater flexibility of vaccination programs by making them more accessible to the public, as well as increase vaccination efficiency.